Jeffrey C. Goh

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Mónica Tang, Rachel O’Connell, Frédéric Amant et al. · Gynecologic Oncology · 2019 · 88 citations · Full text

Medicine, Gynecology, Oncology +14

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Sarah P. Blagden, Anne Hamilton, Linda Mileshkin et al. · Clinical Cancer Research · 2018 · 66 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903

Linda Mileshkin, Richard J. Edmondson, Rachel O’Connell et al. · Gynecologic Oncology · 2019 · 61 citations

Medicine, Gynecology, Oncology +11